Nurix Therapeutics, Inc. NRIX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.78M+27.2% | $83.98M+54.0% | $83.69M+48.3% | $88.38M+41.9% | $56.42M-30.3% | ||
| $331.38M+37.3% | $316.9M+43.0% | $301.1M+47.5% | $270.46M+37.6% | $241.29M+24.8% | ||
| $55.7M+21.6% | $52.74M+14.8% | $49.81M+8.3% | $48.37M+7.7% | $45.8M+2.0% | ||
| $387.08M+34.8% | $369.65M+38.1% | $350.92M+40.3% | $318.84M+32.1% | $287.09M+20.5% | ||
| $387.08M+34.8% | $369.65M+38.1% | $350.92M+40.3% | $318.84M+32.1% | $287.09M+20.5% | ||
| -$315.3M-36.7% | -$285.67M-34.1% | -$267.23M-38.0% | -$230.45M-28.7% | -$230.67M-46.6% | ||
| -439.3%-30.4pp | -340.2%+50.4pp | -319.3%+24.0pp | -260.8%+26.7pp | -408.9%-214pp | ||
| $20.78M-7.5% | $21.97M+11.4% | $23.21M+36.6% | $23.98M+67.9% | $22.45M+77.0% | ||
| -$295.28M-41.7% | -$264.46M-36.6% | -$244.79M-38.3% | -$207.32M-25.6% | -$208.4M-44.0% | ||
| -411.4%-42.0pp | -314.9%+39.9pp | -292.5%+21.2pp | -234.6%+30.3pp | -369.4%-190pp | ||
| -$3.17-13.2% | -$3.05-5.5% | -$2.97-2.1% | -$2.61+10.6% | -$2.80-5.3% | ||
| -$3.17-13.2% | -$3.05-5.5% | -$2.97-2.1% | -$2.61+10.6% | -$2.80-5.3% | ||
| 364.8M+27.6% | 338.3M+31.5% | 318.7M+30.4% | 307.3M+36.0% | 285.8M+31.2% | ||
| 364.8M+27.6% | 338.3M+31.5% | 318.7M+30.4% | 307.3M+36.0% | 285.8M+31.2% | ||
| $20.78M-7.5% | $21.97M+11.4% | $23.21M+36.6% | $23.98M+67.9% | $22.45M+77.0% | ||
| $71.78M+27.2% | $83.98M+54.0% | $83.69M+48.3% | $88.38M+41.9% | $56.42M-30.3% | ||
| -$315.3M-36.7% | -$285.67M-34.1% | -$267.23M-38.0% | -$230.45M-28.7% | -$230.67M-46.6% | ||
| -$306.71M-38.8% | -$276.93M-35.9% | -$258.06M-39.5% | -$220.92M-29.3% | -$221.05M-47.9% | ||
| -$306.71M-38.8% | -$276.93M-35.9% | -$258.06M-39.5% | -$220.92M-29.3% | -$221.05M-47.9% | ||
| -427.3%-35.5pp | -329.8%+43.7pp | -308.4%+19.5pp | -250%+24.3pp | -391.8%-207pp | ||
| -$315.3M-36.7% | -$285.67M-34.1% | -$267.23M-38.0% | -$230.45M-28.7% | -$230.67M-46.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nurix Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.